← Back to all trials
Recruiting
NCT05692596
The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
Conditions: Pancreatic Ductal Adenocarcinoma, Pancreatic Cyst, Chronic Pancreatitis, Fatty Pancreas, Genetic Pancreatic Cancer, Genetic Pancreatitis, BRCA Mutation, Lynch Syndrome, FAP, Familial Atypical Multiple Mole-Melanoma, PALB2 Gene Mutation, Peutz-Jeghers Syndrome, Ataxia Telangiectasia
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: 1
Enrollment: 500
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Location: United States
Summary
The long-term goal of our PIC is to develop effective strategies that can be applied clinically at the point-of-care to prevent, intercept, or detect PDAC at an early stage, thereby reducing PDAC burden and saving lives.
Eligibility Criteria
Inclusion Criteria:18 years of age or olderMoffitt Cancer Center patients presenting with a pancreatic cyst, and/or inherited syndrome that predisposes them to pancreatic ductal adenocarcinoma (PDAC)Moffitt Cancer Center patients undergoing evaluation for localized/early stage PDAC.Moffitt Cancer Center patients with a combination of PDAC risk factors such as a history of chronic or new-onset diabetes, pancreatitis, obesity, tobacco exposure, toxin exposure and/or heavy alcohol consumption.
Source: ClinicalTrials.gov (NCT05692596). StuddyBuddy aggregates publicly available trial information.
